Research Hospital started a new clinical trial of Immune Response evaluation in Oligorecurrent and Oligoprogressive Prostate Cancer patients treated with SBRT
Photo by Ibrahim Boran
Humanitas Research Hospital (Istituto Clinico Humanitas) is starting a new clinical trial of Immune Response Evaluation in Oligorecurrent and Oligoprogressive Prostate Cancer Patients Treated With SBRT.
The hypothesis underlying this project consists in the idea that the patient's immunological context, RT and ADT may interact in the context of metastatic PC. Indeed the immune landscape of patients may interfere with the efficacy of SBRT and on the other side RT may modulate the immune response by driving immunotolerance.
Scope of the study will be to investigate the immune modulation after SBRT in:
- patients with diagnosis of oligorecurrence during a treatment-free interval
- patients with oligoprogression or oligopersistance during hormonal therapy
The clinical trial started in October 19, 2020 and will continue throughout October 2024.
Prostate cancer (PC) represents the second most common cancer in men worldwide, managed with surgery or radiotherapy (RT) in case of localized disease. Advanced PC can metastasize and often presents as an oligometastatic state, defined as an intermediate state between localized and widespread diffused disease. Oligometastatic PC is characterized by the presence of a limited number of metastases, commonly 1 to 5 lesions. Recently, the ESTRO-EORTC collaboration characterized the oligometastatic disease and provided a classification into oligorecurrence, and oligoprogression, considering whether oligometastatic disease is diagnosed during a treatment-free interval or during active systemic therapy. Most common sites of metastases from PC are bones and lymph nodes.
The contacts and locations are the Humanitas Research Hospital, Rozzano, Milano, Italy.
For more details: https://ichgcp.net/clinical-trials-registry/NCT04624828.
